• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward Revenues Up 27%, CFO to Retire

Phase Forward Revenues Up 27%, CFO to Retire

February 6, 2009
CenterWatch Staff

Waltham, Mass.-based eClinical technology company Phase Forward reported a strong fourth quarter and year end 2008, posting a 27% increase in revenues for the year and a 28% increase in revenues in Q4 compared with  the same period last year.

Revenues for the full year 2008 were $170.2 million, up from $134.3 million for 2007. Revenues for the fourth quarter were $48.3 million, up from $37.8 million in Q4 last year. According to a company release, this is Phase Forward’s 18th consecutive quarter of growth since its IPO in 2004.

Despite an increase in revenues, net income for the company fell year-over-year from $29.2 million, or $0.72 per diluted share, in the full year 2007 to $13.8 million, or $0.32 per diluted share, for the full year 2008. Net income for the fourth quarter was $5.8 million, or $0.13 per diluted share, which was at the high end of the company’s guidance of $0.12 to $0.13.

Phase Forward forecast strong revenue growth for 2009 but warned that current economic conditions could provide challenges. For the full year 2009, the company expects non-GAAP revenues to be between $200 and $205 million.

 “The fourth quarter was a strong finish to a highly successful year for Phase Forward, with both the traditional Phase Forward business as well as our recently acquired Clarix™ offering delivering better than expected revenues. We were particularly pleased to sign multi-million dollar, multi-year contract extensions and expansions with some of the largest companies in the pharmaceutical industry, said Phase Forward president and CEO Bob Weiler in a company release. “In addition, the continued traction of our CRO partnering strategy contributed to over 40% growth in our CRO-related revenues during the fourth quarter."

Phase Forward also announced that chief financial officer Rodger Weismann will retire June 1, 2009. Current vice president of finance Chris Menard will replace Weismann as CFO.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing